Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.
Interleukin-1 alpha significantly potentiated the cytotoxicity of carboplatin (8-fold) and camptothecin (4-fold) during simultaneous drug exposure in human ovarian NIH: OVCAR-3 cancer cells in vitro. Treatment of human ovarian tumor cells grown as xenografts in nude mice with IL-1 alpha followed by either carboplatin or CTP-11 at minimally toxic doses significantly (2-3-fold and 7-fold for carboplatin and CTP-11, respectively) enhanced antitumor activity of either agent alone, indicating that IL-1-alpha-drug combinations may be potentially more effective for the treatment of ovarian tumors, including those difficult to cure in the clinic.
Wang
Z
Z
Biochemical and Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Benchekroun
M N
MN
Sinha
B K
BK
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002166:Camptothecin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured
D007375:Interleukin-1; D016190:Carboplatin; D002166:Camptothecin